Psoriasis Humiras sikkerhed og effekt blev undersøgt hos voksne patienter med kronisk plaque- psoriasis (≥ 10% BSA- involveret og Psoriasis- Area - og Severity- Index (PASI) ≥ 12 eller ≥ 10), som var kandidater til systemisk behandling eller lysbehandling i randomiserede, dobbelt- blinde forsøg.
Psoriasis The safety and efficacy of Humira were studied in adult patients with chronic plaque psoriasis (≥ 10% BSA involvement and Psoriasis Area and Severity Index (PASI) ≥ 12 or ≥ 10) who were candidates for systemic therapy or phototherapy in randomised, double-blind studies.